BEIJING--(BUSINESS WIRE)--Oct 26, 2023--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of the CompanyÄ¢¹½ÊÓÆµ BTK ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 26, 2023--Foundation Medicine, Inc., today announced its participation in the National Cancer InstituteÄ¢¹½ÊÓÆµ (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in ...